Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2012 - 2026)

Enanta Pharmaceuticals' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 373.33% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.5 million (down 177.07% YoY) and the FY2025 annual result came in at $40.3 million, down 30.72% from the prior year.
• Cash from Investing Activities was $11.9 million for Q1 2026 at Enanta Pharmaceuticals, up from -$47.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $68.9 million in Q4 2024 and bottomed at -$145.7 million in Q2 2023.
• A 5-year average of $1.1 million and a median of $11.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 998.57% — and 2024, when it soared 625.3%.
• Enanta Pharmaceuticals' Cash from Investing Activities stood at $33.6 million in 2022, then slumped by 139.07% to -$13.1 million in 2023, then surged by 625.3% to $68.9 million in 2024, then sank by 168.64% to -$47.3 million in 2025, then jumped by 125.25% to $11.9 million in 2026.
• Business Quant data shows ENTA's Cash from Investing Activities at $11.9 million in Q1 2026, -$47.3 million in Q4 2025, and $2.3 million in Q3 2025.